PARP抑制剂在BRIP1缺陷卵巢上皮细胞中诱导合成致死
该研究在中国仓鼠卵巢上皮细胞中分别缺陷BRIP1或BRCA1,并暴露于奥拉帕利单药或联合卡铂/顺铂。结果显示BRIP1缺陷细胞对奥拉帕利单药无反应,但铂类联合奥拉帕利产生合成致死效应,提示BRIP1缺陷卵巢癌可能受益于铂类/PARP抑制剂联合方案。
要点
- BRIP1缺陷导致同源重组缺陷,但奥拉帕利单药不降低细胞存活。
- 铂类联合奥拉帕利在BRIP1缺陷细胞中显示协同致死效应。
- BRIP1状态可能指导卵巢癌精准治疗中铂类/PARPi联合方案的选择。
核心结论
- BRIP1缺陷卵巢上皮细胞同源重组功能受损,铂类联合PARP抑制剂可诱导合成致死。
- 奥拉帕利单药对BRIP1缺陷细胞无效,可能与BRIP1分子特性或基因组背景有关。
研究设计与样本
- 工程化中国仓鼠卵巢上皮细胞表达缺陷BRIP1或BRCA1,暴露于奥拉帕利单药或联合卡铂/顺铂。
- 评估细胞增殖与存活,计算抑制浓度及联合与缩减药物指数。
主要发现
- BRIP1和BRCA1失活均阻碍同源重组活性,降低细胞增殖并损害DNA损伤恢复。
- 铂类暴露损害细胞存活。
- 奥拉帕利单药降低BRCA1缺陷细胞活力,但对BRIP1缺陷细胞无影响。
- 卡铂或顺铂联合奥拉帕利协同削弱细胞存活,符合合成致死。
临床怎么用
- 对于BRIP1缺陷的卵巢癌,可考虑铂类联合PARP抑制剂的精准治疗策略。
- 奥拉帕利单药可能不适用于BRIP1缺陷肿瘤,需结合基因组背景评估。
局限性
- 研究使用中国仓鼠卵巢上皮细胞模型,非人源肿瘤细胞或临床样本。
- BRIP1缺陷对奥拉帕利单药无反应的具体机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pathogenic variations in the homologous recombination (HR) gene, BRCA1 interacting protein C-terminal helicase 1 (BRIP1) increase the risk for ovarian cancer. PARP inhibitors (PARPi) exert a synthetic lethal effect in BRCA-mutated ovarian cancers. Effective HR requires cooperation between BRCA1 and BRIP1; therefore, BRIP1-incompetancy may predict vulnerability to synthetic lethality. Here we investigated the response of ovarian epithelial cells with defective BRIP1 function to PARPi, and compared these cells to those lacking BRCA1 activity. METHODS: We engineered Chinese Hamster ovarian (CHO) epithelial cells to express deficient BRIP1 or BRCA1, and exposed them to olaparib with or without carboplatin or cisplatin. We assessed cellular proliferation and survival; we calculated inhibitory concentrations and combination and reduction drug indices. RESULTS: BRIP1 and BRCA1 inactivation impedes HR activity, decreases cellular proliferation and compromises DNA damage recovery. Platinum agent exposure impairs cellular survival. Olaparib exposure alone decreases cell viability in BRCA1-deficient cells, although has no effect on BRIP1-deficient cells. Combining carboplatin or cisplatin with olaparib synergistically attenuates cellular survival, consistent with synthetic lethality. CONCLUSIONS: BRIP1-deficient ovarian epithelial cells exhibit defective HR, resulting in synthetic lethality when exposed to a platinum agent/PARPi combination. PARPi alone had no effect; this lack of effect may result from distinguishing molecular properties of BRIP1and/or consequences of genomic background. Our study identifies altered BRIP1 as a target for precision medicine-based therapies for ovarian cancers. This investigation supports consideration of the use of a platinum agent/PARPi combination in ovarian cancers depending upon genetic profile and genomic background.
引用
- Ciccone MA, Adams CL, Bowen C, et al. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecol Oncol. 2020. PMID: 33032822. doi:10.1016/j.ygyno.2020.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。